PROTHERA BIOLOGICS, LLC

Basic Information

349 Eddy Street
PROVIDENCE, RI, 02903-

Company Profile

n/a

Additional Details

Field Value
DUNS: 140315248
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Therapeutic Role of Inter-alpha Inhibitors in Wound Healing

    Amount: $224,688.00

    DESCRIPTION provided by applicant Wound healing is an intricately regulated process broadly characterized by phases of inflammation proliferation and remodeling Imbalances in any one of these ph ...

    SBIR Phase I 2015 Department of Health and Human Services National Institutes of Health
  2. Inter-alpha-inhibitors in Hypoxic-Ischemic Brain Injury

    Amount: $203,226.00

    DESCRIPTION (provided by applicant): Neonatal hypoxia-ischemia (HI) remains a major cause of acute perinatal brain injury, leading ultimately to neurologic dysfunction manifesting as cerebral palsy, ...

    SBIR Phase I 2014 Department of Health and Human Services
  3. Rapid detection of neonatal sepsis

    Amount: $498,061.00

    DESCRIPTION (provided by applicant): The primary goal of this proposed research is to develop a rapid point-of-care (POC) test that can be used to identify neonatal sepsis in high-risk infants in a si ...

    SBIR Phase I 2012 Department of Health and Human Services
  4. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    Amount: $2,679,880.00

    DESCRIPTION (provided by applicant): Anthrax is recognized as a class A bio-threat microbial pathogen that is readily weaponized and exceedingly difficult to treat. This bacterium is highly virulent i ...

    STTR Phase II 2010 Department of Health and Human Services
  5. Bioprocessing of Plasma Therapeutic Proteins using Sequential Affinity Monolithic

    Amount: $170,547.00

    DESCRIPTION (provided by applicant): Plasma fractionation is one of the largest industry segments in global therapeutic protein manufacture. The United States plays an important role in this industry ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. Role of Inter-alpha Inhibitors in Anthrax Intoxication

    Amount: $1,000,000.00

    DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor proteins (lalp) as an effective protective agent against exp ...

    STTR Phase I 2006 Department of Health and Human Services
  7. Inter-alpha Inhibitors in Detecting CNS Cancer

    Amount: $139,911.00

    DESCRIPTION (provided by applicant) The overall goal is to develop a marketable novel predictive marker based on inter-alpha inhibitor proteins (laIp) in cerebrospinal fluid (CSF) that can be utili ...

    SBIR Phase I 2005 Department of Health and Human Services
  8. THERAPEUTIC USE OF INTER-ALPHA INHIBITOR IN SEPSIS

    Amount: $1,501,420.00

    DESCRIPTION (provided by applicant): The goal of the proposed research is to demonstrate that Inter-alpha serine protease inhibitor proteins (IaIp) are an effective therapy for sepsis. In sepsis, n ...

    SBIR Phase II 2004 Department of Health and Human Services
  9. Predictive value of inter-alpha inhibitors in sepsis

    Amount: $131,233.00

    DESCRIPTION (provided by applicant): The primary goal of this proposal is to demonstrate the feasibility of utilizing Inter-alpha Inhibitor as a novel predictive marker for adult and newborn sepsis ...

    SBIR Phase I 2003 Department of Health and Human Services
  10. THERAPEUTIC USE OF INTER-ALPHA INHIBITOR IN SEPSIS

    Amount: $143,105.00

    The primary goal of this proposed research is targeted towards demonstrating the commercial utilization of human plasma derived inter- alpha inhibitor proteins (IaIp) an effective therapy of sepsis. I ...

    SBIR Phase I 2002 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government